贝伐珠单抗联合紫杉醇治疗非小细胞肺癌过程中并发支气管胸膜瘘1例报告及文献复习

doi:10.13481/j.1671-587X.20220231

Abstract

Abstract: Objective

To investigate the possible mechanism， clinical manifestations and prevention strategies of bronchopleural fistula （BPF） complicated in the treatment of non-small cell lung cancer （NSCLC） by bevacizumab combined with paclitaxel （albumin-binding type），and to identify the individuals with potential risk in time，and to provide the reference for the prevention of this disease.

Methods

The clinical data of one patient with bronchopleural fistula（BPF） complicated in the treatment of NSCLC by bevacizumab combined with paclitaxel （albumin binding type） were collected，and the relevant literatures were reviewed and the potential risk of occurrence was summarized.

Results

A 62-year-old male patient with locally advanced lung adenocarcinoma （negative drive gene） was administered with bevacizumab and paclitaxel （albumin bound） chemotherapy. After 2 cycles of chemotherapy， the patient’s clinical symptoms and functional status were improved. However， due to acute BPF and secondary intrathoracic infection， the patient was forced to stop anti-angiogenic therapy and chemotherapy. Although closed thoracic drainage， active anti-infection treatment and optimal supportive treatment were performed，the clinical symptoms were not relieved.The patient died of respiratory failure on September 17， 2019.

Conclusion

Acute BPF should be induced when the lesions invades pleura， trachea and chest wall simultaneously， and the tumor cavitation effect occurred during the treatment of bevacizumab combined with chemotherapy or the tumor cavity existed in the lesions before treatment.Due to the lack of effective prevention and treatment measures for acute BPF，timely identification of the individual patients with potential risks is crucial to the prognosis.

Key words: Bevacizumab, Bronchopleural fistula, Cancer，non-small cell lung, Anti-angiogenesis, Chemotherapy

CLC Number:

R734.2

Junjie HOU,Xuguang MI,Xiaonan LI,Xiaonan LI,Ying YANG,Xianzhuo JIANG,Ying ZHOU,Zhiqiang NI,Ningyi JIN,Yanqiu FANG. Bronchopleural fistula complicated in treatment process of non-small cell lung cancer by bevacizumab combined with paclitaxel: A case report and literature review[J].Journal of Jilin University(Medicine Edition), 2022, 48(2): 513-517.

Figures/Tables 3

References 24

1	CERFOLIO R J. The incidence，etiology，and prevention of postresectional bronchopleural fistula［J］. Semin Thorac Cardiovasc Surg，2001， 13（1）：3-7.
2	VAROLI F， ROVIARO G， GRIGNANI F，et al. Endoscopic treatment of bronchopleural fistulas［J］. Ann Thorac Surg，1998，65（3）：807-809.
3	王鑫，支修益.国际肺癌研究协会（IASLC）第八版肺癌TNM分期解读［J］.中华胸部外科电子杂志，2016，3（2）：70-76.
4	ETTINGER D S， WOOD D E， AISNER D L，et al. Non-Small Cell Lung Cancer，Version 5.2017，NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw，2017，15（4）：504-535.
5	FERRARA N， HILLAN K J， GERBER H P，et al. Discovery and development of Bevacizumab，an anti-VEGF antibody for treating cancer［J］. Nat Rev Drug Discov 2004，3（5）：391-400.
6	赵维，付彤，刘国津，等.微血管密度和血管内皮因子在肺癌组织中的表达及临床意义［J］.吉林大学学报（医学版），2005，31（4）：595-597.
7	王广义，王旭，谭毓铨.血管内皮生长因子及其受体与肿瘤生长的研究进展［J］.吉林大学学报（医学版），2004，30（2）：316-317.
8	LOPEZ-CHAVEZ A， YOUNG T， FAGES S，et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer， clinical patterns， and outcomes in the Eastern Cooperative Oncology Group 4 599 Study：results of an exploratory analysis［J］. J Thorac Oncol，2012，7：1707-1712.
9	ZHOU C， WU Y L， CHEN G，et al. A Randomized，double-blind，placebo-controlled，multicenter，phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung lancer［J］. J Clin Oncol，2015，33：2197-2204.
10	NISHINO M， CRYER SK， OKAJIMA Y，et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab［J］. Cancer Imaging，2012，12：225-235.
11	KAWASAKI K， HAMAMOTO Y， ADACHI M，et al. Early tumor cavitation with regorafenib in metastatic colorectal cancer： A case report［J］. Oncol Lett， 2016，11：231-233.
12	PENG Y， CHEN Y， ZHANG X，et al. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy［J］. J Cancer Res Clin Oncol，2018，144：1339-1346.
13	ZHANG Y， YANG H， ZHAO M，et al. Bilateral pneumothorax after bevacizumab-containing chemotherapy in fibrosarcoma［J］. J Thorac Dis， 2012， 4（2）： 229-231.
14	BIRAN H， DGANI R， WASSERMAN JP，et al. Pneumothorax following induction chemotherapy in patients with lung metastases： a case report and literature review［J］. Ann Oncol，1992，3： 297-300.
15	FERNANDEZ-RODRIGUEZ L， LINARES-BELTRAN A， TORRES-SANCHEZ I，et al. Cavitating lung cancer as response to bevacizumab treatment［J］. Arch Bronconeumol，2016，52： 531-532.
16	OZAKI Y， YOSHIMURA A， SAWAKI M，et al. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use： A case report［J］. World J Clin Oncol，2020，11：504-509.
17	LI D， WEI G， LI L，et al. Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment：A case report［J］. Mol Clin Oncol，2019，11： 595-598.
18	NISHINARI Y， KASHIWABA M， UMEMURA A，et al. Pulmonary hilar lymph node metastasis of breast cancer induced bronchopleural fistula and superior vena cava syndrome［J］. Am J Case Rep，2014，15：492-495.
19	COHEN L， NEUHAUS S， CHRYSSIDIS S，et al. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma［J］. ANZ J Surg，2017，87：E48-E49.
20	TSAI YM， CHEN SL， HSIEH CM，et al. Treatment of empyema and bronchopleural fistula by bovine pericardium and latissimus flap［J］. Ann Thorac Surg，2013，95（2）：e39-40.
21	BOUDAYA MS， SMADHI H， ZRIBI H，et al. Conservative management of postoperative bronchopleural fistulas［J］. J Thorac Cardiovasc Surg，2013，146： 575-579.
22	UENO T， MAKI Y， SUGIMOTO R，et al. Therapeutic Outcomes of 15 Postoperative Bronchopleural Fistulas Including Seven Endoscopic Interventions［J］. Acta Med Okayama，2019，73：325-331.
23	GURSOY S， YAZGAN S， UCVET A，et al. Postpneumonectomy bronchopleural fistula in non-small cell lung cancer patients：incidence，survival，mortality，and treatment analysis［J］.Surg Today，2018，48（7）：695-702.
24	GARCIA J， HURWITZ HI， SANDLER AB，et al. Bevacizumab （Avastin（R）） in cancer treatment：A review of 15 years of clinical experience and future outlook［J］. Cancer Treat Rev，2020，86：102017.

[1]	Yingjun REN, Hui ZHANG, Ying ZHOU. Inhibitory effects of centromere protein U knockdown on self-renewal, cisplatin resistance and Wnt/β-catenin signaling activity in cisplatin resistant ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 608-614.
[2]	Qing WANG,Siqi XIE,Kai ZHENG,Yiyin TANG,Hongwan LI,Hengyu ZHANG,Mingjian TAN,Lei PENG,Dequan LIU,Shicong TANG. Detection of serum vitamin-B levels in breast cancer patients receiving different chemotherapy regimens and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 724-730.
[3]	Ye YUAN,Jinbao ZHUANG,Xu SHI,Changyuan LI. Influence of PGE2 on PD-1 expression in infiltrating T lymphocytes in non-small cell lung cancer tissue and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(2): 249-256.
[4]	WANG Shaoheng, LIU Pengfei, GAO Teng, GUAN Lei. Analgesic effects of different anesthesia methods on early pain of patients after hyperthermie intraperitoneal chemotherapy [J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1043-1049.
[5]	LIU Hui, MA Yunfei, LIU Bailong, LIU Min. Anlotinib combined with thoracic radiotherapy in treatment of recurrent and refractory small cell lung cancer: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 394-398.
[6]	LI Ruiyang, LIN Zhiyi, LI Jing, FEI Jing, XU Dan, GONG Ping. Changes of IGF-1 and mTOR expressions in peripheral blood of patients with non-small cell lung cancer before and after chemotherapy combined with metformin and analysis on their therapeutic effects [J]. Journal of Jilin University(Medicine Edition), 2020, 46(01): 108-115.
[7]	WANG Shuang, KANG Lihua, GUAN Meng, WANG Lei, LI Beibei, ZHAO Yue, SONG Yanqiu, YANG Tingting. Clinical application of apatinib mesylate combined with chemotherapy in treatment of patients with advanced breast cancer [J]. Journal of Jilin University(Medicine Edition), 2019, 45(05): 1152-1158.
[8]	WANG Zhijing, SU Rongjian, DU Xiaoyuan. Effects of GRP78 on sensibility of gemcitabine on patients with NSCLC [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 595-600.
[9]	ZHU Xiaopeng, LIU Bailong, GUO Liang, LIU Hui, LI Cheng, LIU Min, DONG Lihua. Long-term disease-free survival in patient with laryngeal small cell neuroendocrine carcinoma: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(02): 405-409.
[10]	CAO Wenbin, LIU Qingzhen, ZHOU Lukun, ZHENG Xiaohui, CHEN Shulian, ZHANG Rongli, HE Yi, FENG Sizhou, HAN Mingzhe, YANG Donglin. Pneumocystis jirovecii pneumonia in non-HIV-infected patients with acute leukemia after chemotherapy: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 148-152.
[11]	LI Lijing, ZANG Yaru, YU Wenhui, LIANG Junwei, TONG Yanjun. Therapeutic effect of chemotherapy combined with sodium cantharidinate vitamin B6 injection in patientswith non-small cell lung cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1286-1290.
[12]	YANG Wenyan, LIU Qiang, SUN Zhijuan, DU Liqing, XU Chang, WANG Yan, LIU Yang, WANG Qin. Effect of melatonin on radiosensitivity of non-small cell lung cancer H1299 cells [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 532-536.
[13]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[14]	MA Hongyun, ZHUANG Xinming, XU Weiguo, LIU Yi. Inhibitory effects of hyaluronic acid nanoparticles loading doxorubicin and cisplatin on allograft breast cancer in mice [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 243-248.
[15]	LI Xiaoxia, SUN Yan, QU Rongfeng, REN Lishen, LI Yarong. Primary breast diffuse large B-cell lymphoma: A report of 3 cases and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 166-169.

Bronchopleural fistula complicated in treatment process of non-small cell lung cancer by bevacizumab combined with paclitaxel: A case report and literature review

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 24

Related Articles 15

Metrics

Comments

Recommended 0